:
Alzheimer's disease (AD) is an irrevocable chronic brain disorder featured by neuronal loss, microglial
accumulation, and progressive cognitive impairment. The proper pathophysiology of this life-threatening disorder is not
completely understood and no exact remedies are found yet. Over the last few decades, research on AD has mainly
highlighted in pathomechanisms linked to a couple of the major pathological hallmarks, including extracellular senile
plaques, made of amyloid-β (Aβ) peptides, and intracellular neurofibrillary tangles (NFTs), made of tau proteins. Aβ can
induce apoptosis, trigger an inflammatory response, and inhibit the synaptic plasticity of the hippocampus, which
ultimately contributes to reducing cognitive functions and memory impairment. Recently, a third disease hallmark, the
neuroinflammatory reaction that is mediated by cerebral innate immune cells, has become a spotlight in the current
research area, assured by pre-clinical, clinical, and genetic investigations. Nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB), a cytokine producer, is significantly associated with physiological inflammatory proceedings
and thus showing a promising candidate for inflammation-based AD therapy. Recent data reveal that phytochemicals
mainly polyphenols compounds exhibit potential neuroprotective functions and it may be considered as a vital resource
for discovering several drug candidates against AD. Interestingly, phytochemicals can easily interfere with the signaling
pathway of NF-κB. This review represents the anti-neuroinflammatory potential of polyphenols as inhibitors of NF-κB to
combat AD pathogenesis.
An Assay for Screening Potential Drug Candidates for Alzheimer's Disease That Act as Chaperones of the Transthyretin and Amyloid‐β Peptides Interaction
